L-Carnitine vs Survodutide
A side-by-side research comparison of L-Carnitine and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | L-Carnitine | Survodutide |
|---|---|---|
| Full name | L-Carnitine Injectable | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Supplement / Compounded | Phase 3 Clinical Trial |
| Mechanism | Transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle, enabling beta-oxidation for ATP production. Also reduces oxidative stress and supports cardiac function. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 161.20 Da | 4,500 Da (approximate) |
| Half-life | ~2-3 hours (IM) | 5-7 days |
| Bioavailability | ~100% injectable; ~14-18% oral | High (SubQ) |
| Typical dose | 500-2000 mg | 0.6-6.0 mg |
| Frequency | 2-5x per week | Once weekly |
| Route | Intramuscular or IV injection | Subcutaneous |
L-Carnitine reported benefits
- Enhanced fat oxidation
- Improved energy
- Exercise performance
- Cardiac health
- Recovery support
- Mitochondrial function
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.